Proton Pump Inhibitors (PPIs): Is Perpetual Prescribing Inevitable?

Clinical Question: How successful are attempts to stop PPIs and how can clinicians improve chances of success?

Bottom Line: Using a range of deprescribing strategies, about 25% of patients with gastroesophageal reflux disease (GERD) or dyspepsia can stop PPI use and another 30-50% can decrease their dose. Older patients and those who taper appear more successful in stopping PPIs.

Evidence:

- Clustered randomized controlled trials:
  - Patients (n=196) taking twice daily PPIs for >8 weeks were randomized to receive information pamphlets with academic detailing for their physician versus standard care.\(^1\) At six months:
    - 30% stopped PPI or changed to Histamine Receptor Antagonists (H2RA) versus 19% in control group, Number Needed to Treat (NNT)=10.
    - Additional 50% reduced PPI dose.
  - 113 dyspeptic patients randomized to receive a letter encouraging stopping/decreasing PPIs or usual care.\(^2\) At 20 weeks:
    - 13% off PPI, compared to 5% in control group (NNT=13).
    - Additional 9% reduced their dose.

- Cohort studies of patients on PPIs for >8 weeks:
  - 73 Veterans with GERD attempted taper then stopping PPI.\(^3\) At one year:
    - 34% switched to H2RA, 15% off all acid reducers.
    - Older patients appeared more successful in stopping.
  - 166 dyspeptic/GERD patients offered \textit{H. Pylori} testing and treatment, then educated about symptoms, lifestyle and PPIs.\(^4\) At one year:
    - 34% stopped, additional 50% reduced their dose.
  - 27 GERD patients reviewed PPI use at periodic health exam.\(^5\) At 10 weeks:
    - Ten (37%) stopped PPI: Six completely, four changed to H2RA.
  - Of 97 predominantly GERD patients with normal gastroscopy, 27% stopped PPIs at one year.\(^6\)
Context:
- ~60% long-term PPI users may not need them.\(^7\)
- PPI use associated with (but causation unclear):
  - *Clostridium difficile* colitis:
    - Community dwelling without antibiotics (1/10,000 risk)\(^8\) to in-hospital on antibiotics and PPIs (8-10% risk).\(^9\)
  - Fractures: Extra one in 2000 women over eight years.\(^10\)
  - Pneumonia.\(^11\)
  - Vitamin B12 and magnesium deficiencies.\(^12,13\)
- Abruptly stopping PPIs may cause transient rebound GERD or dyspepsia symptoms.\(^14,15\)
  - Tapering may help.\(^6\)
- Long-term PPIs should be considered for patients with recurrent symptoms, endoscopic esophagitis, complications from GERD (example: stricture), or those requiring gastroprotection.

Authors:
Michael R. Kolber BSc MD CCFP MSc, Tony Nickonchuk BSc Pharm

Disclosure:
Authors do not have any conflicts of interest to declare.

References:

**Tools for Practice** is a biweekly article summarizing medical evidence with a focus on topical issues and practice modifying information. It is coordinated by G. Michael Allan, MD, CCFP and the content is written by practising family physicians who are joined occasionally by a health professional from another medical specialty or health discipline. Each article is peer-reviewed, ensuring it maintains a high standard of quality, accuracy, and academic integrity. If you are not a member of the ACFP and would like to receive the TFP emails, please sign up for the distribution list at [http://bit.ly/signupfortfps](http://bit.ly/signupfortfps). Archived articles are available on the ACFP website.

This communication reflects the opinion of the authors and does not necessarily mirror the perspective and policy of the Alberta College of Family Physicians.